Who took part in this safety lead-in?
57 People with BRAF V600E–mutant mCRC
27 Participants received encorafenib + cetuximab + mFOLFOX6 treatment
30 Participants received encorafenib + cetuximab + FOLFIRI treatment

People included in the safety lead-in
≥18 Years of age
BRAF V600E–mutant mCRC
Fully active, or able to carry out lighthousework but not strenuous activites
No more than 1 previous systemic treatment for mCRC
Adequate bone marrow, liver, and kidney function

People excluded from the safety lead-in
MSI-H or dMMR tumor (unless patient is unable to receive immune checkpoint inhibitors)
Cancer has spread to the brain and is causing symptoms
Previous treatment with drugs blocking BRAF or EGFR